Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Current history of SBS as a result of major intestinal resection, (eg, due to necrotizing enterocolitis, midgut volvulus, intestinal atresia, or gastroschisis) for at least 12 months prior to screening~* Short bowel syndrome that requires parenteral nutrition/intravenous (PN/IV) support~* Stable PN/IV support for at least 3 months prior to enrollment based upon the opinion of the investigator~Key Exclusion Criteria:~* Serial transverse enteroplasty or any other bowel lengthening procedure performed within the past 3 months~* Unstable absorption due to cystic fibrosis, untreated Hirschsprung's disease or known DNA abnormalities (ie, Familial Adenomatous Polyposis, Fanconi syndrome)~* Evidence of obstruction on upper gastrointestinal (GI) series done within 6 months prior to screening~* Major gastrointestinal surgical intervention within 3 months prior to screening (insertion of feeding tube or endoscopic procedure is allowed)

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- teduglutide (Type: EXPERIMENTAL): Open label teduglutide, subcutaneously injected.
- Standard of Care (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).